SCHEMBL1542786

SCHEMBL1542786

CC(C)(C)c1cc(-c2ccccc2)c(O)c(-c2ccc[nH]c2=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PLA2G1B P04054 1/20 0.39
NFKB1 P19838 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
HDAC4 P56524 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MAPT P10636 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542849 0.85 NPC1 (0.41) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1542954 0.83 DAO (0.36) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1542933 0.82 AKR1C2 (0.38) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1543435 0.82 ALDH1A1 (0.40) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1543258 0.82 ALDH1A1 (0.38) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL8900064 0.82 BACE1 (0.47) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1543440 0.81 PTPN1 (0.38) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL200188 0.81 BACE1 (0.49) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1727256 0.80 TRPV1 (0.38) NPC1ALDH1A1PLA2G1BNFKB1CASP3
SCHEMBL1542747 0.78 PARP1 (0.41) ALDH1A1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B NPC1 972/4885ALDH1A1 1136/4885PLA2G1B 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.